Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinol topical
- Development stage
- Phase 2
- Lead developer
- InMed Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Cannabinol topical (INM-755) is a cream formulation containing cannabinol (CBN) as the active pharmaceutical ingredient. It is being developed for the treatment of symptoms associated with epidermolysis bullosa (EB), a rare genetic skin disease characterized by fragile skin that easily blisters and wounds. The drug may help relieve hallmark EB symptoms such as inflammation and pain, as well as potentially enhance skin integrity in a subset of EB Simplex patients. INM-755 is the first cannabinol formulation to be studied in clinical trials as a potential therapeutic to treat disease.
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabinol topical.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinol topical.